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Delivering chemotherapy at home: how much do we know?  
 
Delivering care closer to home has become a priority within the NHS as it reduces 
the burden on secondary and tertiary care while maximising convenience to the 
patient and supporting the ethos of person-centred care. 
Home chemotherapy is one example of such care as it allows patients to receive 
their treatment in the comfort of their home avoiding the stress and inconvenience of 
hospital visits (Corbett et al 2015). 
Traditionally, home chemotherapy entails the delivery of the treatment under  
supervision by a specialised  nurse. With the advent of ambulatory devices, this term 
has evolved to include ambulatory chemotherapy. These devices, also known as 
infusion pumps, allow patients to safely receive prolonged infusions unsupervised 
with community nurses visiting the patient at the end of the infusion to disconnect the 
device. 
Specialised community nurses can deliver a range of chemotherapeutic agents at 
home that differ in complexity. Some agents such as intravenous cytarabine used for 
the treatment of paediatric leukaemia are described by community nurses as simple 
due to the small volume involved. While others such as subcutaneous azacitidine for 
myelodysplastic syndromes (MDS) are more complicated due to the need to 
maintain a cold chain (Murthy et al 2019). 
Infusion pumps can be loosely categorised into mechanical pumps (ex battery 
operated) or elastomeric pumps (infusors). The latter are disposable balloon pumps 
that are silent and light weight. These are used to deliver prolonged infusions at 
home such as 5 fluorouracil for the treatment of bowel cancer. Patients are usually 
connected to these devices at the cancer centre and then visited by the community 
nurses at the end of infusion for disconnection. Patients can also come back to the 
cancer centre to be disconnected. 
With the increased use of this service, nurses were facing a problem that was not 
previously described. When the nurses were presenting to disconnect the 
elastomeric pumps at the scheduled time, they found that some  pumps have not 
finished infusing all the chemotherapy volume. At this point the nurse has two 
options: to disconnect and dispose of  the pump or allow the pump to continue 
infusing. Even though, option one follows the prescribed protocol, it translates into 
patients not receiving their full doses. While option two allows the full dose to be 
infused, it translates into increased patient wait times or disrupted schedules for the 
district/community nurses who have to come back at a later time to disconnect the 
patient. 
Variation in the delivery of home chemotherapy via elastomeric pumps was expected 
but not scientifically measured. Therefore, we initially decided to conduct four 
experiments in the laboratory (Salman et al 2013) whereby we investigated the flow 
rate accuracy and end of infusion time of the commercially available elastomeric 
pumps. Temperature of both the flow controller and the actual elastic reservoir were 
taken into consideration as well as the viscosity of the diluent. The experiment was 
simple, vary both temperature and viscosity and observe how these devices would 
perform. The measured flow rate did not match the specified flow rate, and varied with 
temperature and the viscosity of diluents. However, the temperature around the pump 
changes significantly from user to user and over time. This temperature fluctuation will 
not only cause further inconsistencies in the pump flow rates but also to the stability 
of the chemotherapy regimen.  
The performance of elastomeric pumps was not only affected by the temperature 
surrounding the pumps, but also the viscosity of chemotherapeutic regimes and/or the 
combination of both. The viscosity of chemotherapeutic regimes is unlikely to be the 
same as 0.9% sodium chloride or 5% dextrose solutions used to calibrate the pumps. 
The findings of these simple experiments  concluded that flow rate and end of infusion 
time of elastomeric pumps were affected by different laboratory-based conditions. 
However, these factors are unpredictable and uncontrollable in practice. With all the 
different factors affecting the accuracy of these pumps, it is difficult to duplicate the 
same use conditions experienced during standard clinical practice. There was a need 
to evaluate the performance of these pumps in real practice and while used by the 
patients. 
Consequently, we  conducted a two-phase study (Salman et al 2017) to observe and 
evaluat  patients receiving home chemotherapy via elastomeric pumps (5FU infused 
via a 48 hour elastomeric pump) at three gastrointestinal medical day units (MDU). 
Ethical approval to conduct both phases was sought and granted from the Clinical 
Audit committee (CAC). Phase 1 was an observational cross-sectional study, 
elastomeric pumps connected to patients were observed at connection and 
disconnection in the medical day unit or at home with the help of a district nurse. The 
status of the pump at disconnection time and the volume remaining in the pump were 
recorded. The action taken in the event of unfinished pumps was noted to evaluate 
the hospital policy. Instructions given to patients and nurses actions in the event of an 
unfinished pump were recorded along with the additional time the patient had to wait. 
Results of this phase of the study showed that 50% of the 92 cases/pumps that were 
followed, covering 50 cases disconnected at MDU and 42 at home by community 
nurses, did not finish on time. This had caused not only disruption to some of the 
patients and ambulatory home chemotherapy services but also sub-therapeutic dosing 
as pumps were discarded with left over infusion.  
Results revealed that there was no policy that guides the nurses in the event of fast or 
slow pumps, and therefore the nursing staff had developed different approaches to 
deal with this unexpected variation in performance of elastomeric pumps. These 
approaches included: discard the pump immediately (73%), patient was asked to wait 
in the MDU before disconnection (11%), patient was sent home and asked to come 
back the next day (8%) and patient was given advice over the phone (8%). 
In another study conducted by us at another cancer centre (Saleh et al 2015), similar 
results were observed where a significant number of patients were presenting with 
unfinished pumps. This study also included a survey of the nurses (hospital and 
district) to gauge their knowledge of these pumps.   
50% of the respondents stated that they had no formal training about the elastomeric 
pumps. 
As part of the survey, the nurses were presented with pictures of pumps containing 
different volumes and were asked to choose the pumps which they thought were 
empty. A significant number of nurses misidentified pumps that contained more than 
20mL as empty. 
These findings highlight the need for further nurse support and training with the use of 
the elastomeric pumps. 
Morever, our study also included a patient survey to evaluate their knowledge on 
handling the pump while at home. The results also highlighted gaps in their knowledge 
where some patients were placing the pumps under their pillow while asleep which 
might increase pump ambient temperature. 
It is however important to note that despite all of variations in the performance of 
elastomeric pumps, patients reported high satisfaction with these pumps overall. 
Home chemotherapy with its various forms has revolutionised patient care and has 
been linked with improved patient quality of life.  
However, there are several recommendations to consider to maintain an optimal 
delivery. 
• A Hospital policy to address unfinished pumps 
• Nurse support which includes training on the use of the elastomeric devices 
and spill kits  
• Patient counselling on the handling of the pumps while at home (ex while 
sleeping, bathing etc) and instructions to contact the district nursing team in 
case of fast or slow infusions. 
• Streamlined service where nurses communicate with patients ahead of time to 
plan a suitable disconnection time 
 
• The particular characteristics of the chemotherapy delivered at home 
including stability of the solution (ex azacytidine is only stable for 1 hour at 
room temperature) 
Conclusion 
Delivering chemotherapy at home has become more common with the advent of 
elastomeric pumps. However, nursing staff responsible for connecting or 
disconnecting these pumps at the patients’ homes need to be supported and 
provided with the required training and policies. 
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Abstract 
Ambulatory chemotherapy offers many advantages from supporting a closer to home 
treatment approach to lowering the cost of care. Ambulatory devices such as 
elastomeric pumps can deliver prolonged infusions of a variety of chemotherapy 
agents nowadays.  Elastomeric pumps are preferred by the patients as they get 
them connected at the hospital or cancer centres then go back home where they can 
have visits from the district nursing team.  This supports minimal disruption to 
careers and families . Despite all the advantages, experiments carried out by the 
authors and others in the literature showed that the performance of these pumps 
vary depending on temperature or viscosity of diluent or both. Interestingly, a two-
phase study that was carried out to observe and evaluate GI patients receiving 
ambulatory chemotherapy concluded that in 50% of the observed cases the infusion 
pump did not finish on time. This caused disruption to these patients’ treatment 
schedule and in some cases resulted in sub-therapeutic dosing.   
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CPD questions:  
  
How does ambulatory chemotherapy support person centred care?  
  
What are the limitations of ambulatory chemotherapy?  
  
What is the role of the nurse in ambulatory chemotherapy?  
 
Key points: 
 
-Elastomeric pumps have revolutionised the delivery of chemotherapy at home. 
-The optimised use of elastomeric pumps requires the support and training of the 
nursing staff involved in this service 
-Variations in temperature and solution viscosity affect the infusion rate of 
elastomeric pumps which may lead to sub-therapeutic dosing. 
-Patient education and streamlined communication channels will enhance the 
ambulatory chemotherapy service. 
 
